Amgen Inc. ($AMGN) Stock Forecast: Up 5.0% Today

What is Amgen Inc.?

A leading biotechnology company, Amgen (NASDAQ: AMGN) is recognized for its innovative treatments across various therapeutic areas, particularly in oncology. The company has recently experienced favorable market activity.

Why is Amgen Inc. going up?

AMGN stock is up 5.0% on Jan 7, 2026 14:41

• Amgen's acquisition of Dark Blue Therapeutics for $840 million, aimed at expanding its oncology pipeline, has instilled optimism among investors regarding the company's strategic growth plans.
• The raise in Amgen's dividend to $2.52 indicates a sustainable payout ratio and a robust earnings growth projection, appealing to income-focused investors and contributing to the stock's performance.
• Comparatively, while Regeneron Pharmaceuticals has had quieter institutional appeal, Amgen's proactive stance in bolstering its portfolio and market standing has garnered positive attention.
• The general bullish outlook on Amgen is also influenced by the optimistic prospects within the broader biotech sector, where investors are acknowledging the potential driven by innovative treatments and strategic acquisitions for future growth.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Amgen buys Dark Blue Therapeutics in $840m oncology deal

Amgen has acquired UK-based Dark Blue Therapeutics for up to $840m, marking the first major pharma takeover of 2026. This acquisition grants Amgen access to Dark Blue’s oncology pipeline, including DBT 3757, an investigational treatment for acute myeloid leukaemia. The deal signals Amgen's renewed focus on early-stage drug development and dealmaking after a period of less activity.

https://www.pharmaceutical-technology.com/news/amgen-acquires-dark-blue-therapeutics-oncology-targeted-protein-degrader/

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52

Amgen Inc. (NASDAQ:AMGN) is set to increase its dividend to $2.52, offering a 3.1% yield. The company's dividend payout is considered sustainable, with only 47% of free cash flow being used for payments and a forecast earnings per share growth of 21.3% next year. Despite limited earnings growth over the past five years, Amgen has a solid track record of consistently growing dividends at an average annual rate of 12% since 2016.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-nasdaqamgn-is-increasing-its-dividend-to-252

UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment

UBS has initiated coverage on Viridian Therapeutic with a Buy rating and a $50.00 price target, citing the company's progress with its Thyroid Eye Disease (TED) treatments. The investment bank highlights the potential FDA approval of VRDN-001 by mid-2026 and the significant opportunity presented by VRDN-003, with Phase III data expected in the first half of 2026. This positive outlook is further supported by recent news of the FDA granting Priority Review status for Viridian's Biologics License Application for veligrotug.

https://uk.investing.com/news/analyst-ratings/ubs-initiates-viridian-therapeutic-stock-with-buy-rating-on-ted-treatment-93CH-4441293

The Truth About Regeneron Pharm: Why Everyone Is Suddenly Paying Attention

This article examines Regeneron Pharmaceuticals (REGN), contrasting its quiet institutional appeal with its lack of viral social media presence. It highlights Regeneron's strong pipeline, proven revenue, and long-term uptrend in stock performance, positioning it as a stable, science-backed investment rather than a speculative meme stock. The author concludes that REGN is a "cop" for patient, research-driven investors seeking growth in biotech, despite not offering quick, explosive gains.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-regeneron-pharm-why-everyone-is-suddenly-paying-attention/68465578

Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report

Amgen Inc. has acquired U.K.-based Dark Blue Therapeutics Ltd. gaining a preclinical small molecule targeting MLLT1 and MLLT3 for acute myelogenous leukemia (AML). The deal's total value could reach $840 million based on milestones, though the upfront payment was not disclosed. This acquisition marks a significant biotech M&A transaction early in 2026.

https://www.biocentury.com/article/657985/amgen-adds-aml-candidate-in-deal-for-u-k-based-dark-blue-deals-report

Trending Today

Jupiter ($JUP) Crypto Forecast: Up 13.2% Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 5.0% Today

Natural Gas ($GAS) Commodity Forecast: Down 7.2% Today

ZCash ($ZEC) Crypto Forecast: Up 5.3% Today

Silver ($XAG) Commodity Forecast: Up 6.7% Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.8% Today

Centene Corporation ($CNC) Stock Forecast: Down 10.9% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Down 5.1% Today

Elevance Health Inc. ($ELV) Stock Forecast: Down 14.2% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.3% Today

Amgen Inc. Price History

05.10.2025 - AMGN Stock was up 5.3%

• Q3 earnings and revenues for Amgen (AMGN) surpassed expectations, indicating strong financial performance and potentially positive future outlook.
• Despite a slight decline in the current session, the stock has demonstrated resilience over the past month and year, suggesting a reliable long-term investment opportunity.
• Investors are closely monitoring Amgen's Q3 results, particularly focusing on the impact of newer drugs, biosimilar competition, and pricing pressures on the company's growth trajectory.
• The optimistic sentiment surrounding Amgen's financial performance and strategic positioning likely played a role in the bullish movement in the stock today.

05.10.2025 - AMGN Stock was up 7.7%

• Amgen's strong bullish movement today can be attributed to its impressive Q3 earnings and sales beat, surpassing estimates and showcasing double-digit growth driven by key drugs.
• The company's decision to raise its 2025 outlook has instilled confidence in investors, leading to a positive market response.
• Investors are likely encouraged by the company's ability to consistently outperform expectations, as seen in the significant earnings and revenue surprises for the quarter.
• The market's positive reaction also reflects investors' anticipation of Amgen's future performance, as they delve deeper into the company's potential beyond just headline estimates.

17.03.2025 - AMGN Stock was down 6.3%

• Amgen's stock experienced a bearish movement likely due to the lawsuit filed by Sandoz alleging illegal blocking of biosimilar competition for Enbrel, a significant revenue-generating arthritis drug.
• The legal battle and uncertainty surrounding the availability of Erelzi in the U.S. due to contested patents for Enbrel could have contributed to the negative market sentiment towards Amgen.
• Despite a slight gain in a recent trading session, the overall bearish trend today could be attributed to concerns over potential legal implications and competition affecting Amgen's market position and revenue streams.

07.00.2026 - AMGN Stock was up 5.0%

• Amgen's acquisition of Dark Blue Therapeutics for $840 million, aimed at expanding its oncology pipeline, has instilled optimism among investors regarding the company's strategic growth plans.
• The raise in Amgen's dividend to $2.52 indicates a sustainable payout ratio and a robust earnings growth projection, appealing to income-focused investors and contributing to the stock's performance.
• Comparatively, while Regeneron Pharmaceuticals has had quieter institutional appeal, Amgen's proactive stance in bolstering its portfolio and market standing has garnered positive attention.
• The general bullish outlook on Amgen is also influenced by the optimistic prospects within the broader biotech sector, where investors are acknowledging the potential driven by innovative treatments and strategic acquisitions for future growth.

24.05.2025 - AMGN Stock was down 5.8%

• AMGN's stock price closed at $272.44, representing a significant -5.84% decrease compared to the previous day.
• The market response was influenced by the mixed outcomes of Part 1 of its Phase 2 study of MariTide, causing uncertainty among investors and resulting in downward pressure on the stock.
• Options trading activities indicate a prevailing bearish sentiment, with a majority of traders leaning towards pessimistic positions, exacerbating the selling pressure on AMGN's shares.
• Despite the current downward trend, some investors may view the decline in AMGN's stock price as an opportunity to potentially profit from the company's history of developing cutting-edge therapies in the long run.

05.00.2026 - AMGN Stock was down 1.4%

• The decline in Amgen's stock today may be linked to AbbVie's entry into the lung cancer drug market, potentially posing a competitive challenge for Amgen and affecting investor sentiment.
• Despite Amgen's positive quarterly earnings and dividend increase, market reaction might be influenced by the uncertainty surrounding the impact of AbbVie's new drug.
• Sizeable investments from D.A. Davidson & CO., Greenspring Advisors LLC, and Railway Pension Investments Ltd. indicate confidence in Amgen's future outlook. However, market caution could be attributed to the competitive landscape in lung cancer treatments.
• Overall, market sentiment towards Amgen remains optimistic, evident from analyst ratings and price targets. However, today's bearish trend suggests that investors are attentive to evolving competition within the biopharmaceutical sector.

02.06.2025 - AMGN Stock was up 5.2%

• Bemarituzumab, Amgen's gastric cancer drug, demonstrated enhanced survival rates in Phase 3 trials for advanced gastric cancer patients, likely bolstering investor trust in the company's pipeline and future revenue opportunities.
• The progress of MariTide, a monthly treatment for obesity in late-stage trials, signals Amgen's strategic move into the obesity market, attracting investor attention and optimism.
• The commencement of a Phase 3 study by VKTX on an obesity candidate might suggest growing competition in the obesity treatment sector, yet Amgen's established reputation and robust pipeline could help it maintain a competitive position.
• The prevailing positive market sentiment and Amgen's +1.03% stock price rise may indicate investor confidence in the company's innovative drug pipeline and its potential for future expansion and growth.

06.07.2025 - AMGN Stock was down 5.1%

• Despite surpassing earnings and revenue projections in the second quarter, the stock displayed downward movement.
• The market's reaction may be linked to concerns about the company's future growth potential despite the positive outcomes.
• Investors appear to be capitalizing on gains following a period of robust performance, causing a temporary decline in the stock value.
• Various broader market dynamics such as sector shifts or general market sentiment could be influencing Amgen's stock price negatively.

06.07.2025 - AMGN Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue projections, Amgen (AMGN) faced a downturn in the market today.
• The market's reaction could be attributed to concerns regarding the company's future growth trajectory or provided guidance.
• Investors may have had higher expectations, prompting profit-taking and a temporary decline in the stock value.
• It is crucial to observe how Amgen addresses any potential underlying issues to determine the continuity of this bearish trend or whether it signals a buying opportunity for investors.

06.00.2026 - AMGN Stock was up 2.3%

• AMGN's bullish movement can be attributed to its strategic acquisition of Dark Blue Therapeutics, a UK-based cancer drug developer, in a deal worth up to $840 million. This acquisition expands AMGN's oncology portfolio and strengthens its position in the biotechnology industry.
• The acquisition of Dark Blue Therapeutics adds an investigational small molecule targeting specific types of acute myeloid leukemia (AML) to AMGN's pipeline, showcasing the company's commitment to advancing oncology therapeutics.
• The market likely responded positively to the news as the acquisition aligns with AMGN's research focus on targeted protein degradation and leukemia therapeutics, demonstrating its dedication to enhancing its early oncology discovery efforts.
• Additionally, the promising preclinical data on the anti-cancer activity of the MLLT1/3 protein degrader acquired through this deal further fueled investor optimism in AMGN's future growth prospects in the oncology space.

23.05.2025 - AMGN Stock was down 5.4%

• Today's bearish movement in AMGN may have been driven by market sentiment reflected through options trading, where a majority of traders displayed bearish tendencies.
• Noteworthy bearish actions by financial giants on Amgen might have caused apprehension among investors, prompting a sell-off of the stock.
• The analysis of options history revealing a higher percentage of bearish trades could have intensified the negative sentiment surrounding Amgen and contributed to today's significant bearish movement in the stock.

01.09.2025 - AMGN Stock was up 5.3%

• A noteworthy expansion of $650 million was unveiled by Amgen for its U.S. manufacturing network, reflecting a bolstered confidence in future growth prospects.
• The stock's bullish trend may be attributed to investors' optimism towards Amgen's strategic decision to enhance manufacturing capacity in response to evolving pharmaceutical tariff policies.
• Notwithstanding a minor market downturn, Amgen's proactive measures to reinforce manufacturing capabilities likely instilled confidence among investors, driving the stock's positive performance.